Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jan 31:9:18.
doi: 10.1186/1479-5876-9-18.

The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program

James M Balwit  1 , Patrick Hwu, Walter J Urba, Francesco M Marincola
Affiliations
Review

The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program

James M Balwit et al. J Transl Med. .

Abstract

The Society for Immunotherapy of Cancer, SITC (formerly the International Society for Biological Therapy of Cancer, iSBTc), aims to improve cancer patient outcomes by advancing the science, development and application of biological therapy and immunotherapy. The society and its educational programs have become premier destinations for interaction and innovation in the cancer biologics community. For over a decade, the society has offered the Primer on Tumor Immunology and Biological Therapy of Cancer™ in conjunction with its Annual Scientific Meeting. This report summarizes the 2010 Primer that took place October 1, 2010 in Washington, D.C. as part of the educational offerings associated with the society's 25th anniversary. The target audience was basic and clinical investigators from academia, industry and regulatory agencies, and included clinicians, post-doctoral fellows, students, and allied health professionals. Attendees were provided a review of basic immunology and educated on the current status and most recent advances in tumor immunology and clinical/translational cancer immunology. Ten prominent investigators presented on the following topics: innate immunity and inflammation; an overview of adaptive immunity; dendritic cells; tumor microenvironment; regulatory immune cells; immune monitoring; cytokines in cancer immunotherapy; immune modulating antibodies; cancer vaccines; and adoptive T cell therapy. Presentation slides, a Primer webinar and additional program information are available online on the society's website.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Butterfield LH, Ribas A, Dissette VB, Amarnani S, Vu H, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran A, Glaspy JA, Economou JS. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003;9:998–1008. - PubMed
    1. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu H, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride W, Economou JS, Butterfield LH. Role of dendritic cell phenotype, determinant spreading and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004;27:354–367. doi: 10.1097/00002371-200409000-00004. - DOI - PubMed
    1. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL, Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res. 2010. in press . - PMC - PubMed
    1. Butterfield LH, Disis ML, Khleif SN, Balwit JM, Marincola FM. Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force. J Transl Med. 2010;8(1):130. doi: 10.1186/1479-5876-8-130. - DOI - PMC - PubMed
    1. Biomarkers Symposium Slides. http://www.isbtc.org/meetings/am10/biomarkers10/65

MeSH terms

Substances

LinkOut - more resources